Globenewswire·2025-10-01 11:00Core Insights - Avalo Therapeutics, Inc. has expanded its leadership team with the appointment of Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President of Human Resources, marking a significant phase for the company as it advances its clinical programs [1][2] Leadership Appointments - Taylor Boyd brings nearly 15 years of experience in biotech business development, corporate finance, and investment banking, having previously led strategic initiatives at Abzena and Longboard Pharmaceuticals, including a $2.6 billion acquisition [2][3] - Ashley Ivanowicz has nearly 20 years of experience in HR within the biotech and pharmaceutical sectors, previously serving at Venatorx Pharmaceuticals and advising life sciences companies on people strategies [3][4] Strategic Focus - The company is currently advancing AVTX-009 through the LOTUS Phase 2 trial for hidradenitis suppurativa, with a data readout expected mid-next year [2][6] - Both new leaders are expected to enhance Avalo's ability to execute its mission of developing IL-1β therapies to address significant unmet medical needs [2][3] Stock Options - Avalo's Board of Directors has approved the grant of 275,000 stock options to Mr. Boyd and 100,000 stock options to Ms. Ivanowicz, which will vest over four years [4][5] Company Overview - Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases, with its lead asset AVTX-009 currently in a Phase 2 clinical trial [6][7]